ViroGates (EP2) Stock Overview
An in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EP2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ViroGates A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 1.45 |
| 52 Week High | DKK 2.32 |
| 52 Week Low | DKK 1.05 |
| Beta | 0.64 |
| 1 Month Change | 2.84% |
| 3 Month Change | -2.36% |
| 1 Year Change | 38.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 73.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| EP2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.4% | 1.5% | 1.7% |
| 1Y | 38.1% | -26.8% | 2.6% |
Return vs Industry: EP2 exceeded the German Medical Equipment industry which returned -28.6% over the past year.
Return vs Market: EP2 exceeded the German Market which returned 1.1% over the past year.
Price Volatility
| EP2 volatility | |
|---|---|
| EP2 Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: EP2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EP2's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
ViroGates A/S Fundamentals Summary
| EP2 fundamental statistics | |
|---|---|
| Market cap | €12.67m |
| Earnings (TTM) | -€1.37m |
| Revenue (TTM) | €1.20m |
Is EP2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EP2 income statement (TTM) | |
|---|---|
| Revenue | DKK 9.01m |
| Cost of Revenue | DKK 1.94m |
| Gross Profit | DKK 7.07m |
| Other Expenses | DKK 17.29m |
| Earnings | -DKK 10.22m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 78.46% |
| Net Profit Margin | -113.54% |
| Debt/Equity Ratio | 25.1% |
How did EP2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 09:11 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ViroGates A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.